Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Related Articles by Review for PubMed (Select 18667204)

1.

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan.

Atherosclerosis. 2008 Sep;200(1):135-40. doi: 10.1016/j.atherosclerosis.2008.06.003. Epub 2008 Jun 19. Erratum in: Atherosclerosis. 2009 May;204(1):233.

PMID:
18667204
2.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

3.
4.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
5.
6.

Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.

Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, Saku K.

Circ J. 2013;77(11):2651-63. Epub 2013 Oct 10. Review.

7.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
8.

Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease.

Karalis DG.

Mayo Clin Proc. 2009 Apr;84(4):345-52. doi: 10.1016/S0025-6196(11)60544-2. Review.

9.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
10.

Triglyceride as a risk factor for coronary artery disease.

Gotto AM Jr.

Am J Cardiol. 1998 Nov 5;82(9A):22Q-25Q. Review.

PMID:
9819100
12.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
13.

Pitavastatin: clinical effects from the LIVES Study.

Teramoto T.

Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1. Review.

PMID:
22152283
14.

Recent developments in the treatment of hypertriglyceridemia.

Duriez P, Fruchart JC.

Curr Atheroscler Rep. 1999 Jul;1(1):31-7. Review.

PMID:
11122689
15.

Pitavastatin: an overview.

Saito Y.

Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8. Review.

PMID:
22152281
16.
17.

Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.

Jafri H, Alsheikh-Ali AA, Karas RH.

J Am Coll Cardiol. 2010 Jun 22;55(25):2846-54. doi: 10.1016/j.jacc.2009.12.069. Review.

18.

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

Olsson AG, McTaggart F, Raza A.

Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. Review.

PMID:
12481202
19.

Cholesterol 2001. Rationale for lipid-lowering in older patients with or without CAD.

Aronow WS.

Geriatrics. 2001 Sep;56(9):22-5, 28-30. Review.

PMID:
11582971
20.

Management of hypercholesterolaemia in postmenopausal women.

Davidson MH, Maki KC, Karp SK, Ingram KA.

Drugs Aging. 2002;19(3):169-78. Review.

PMID:
12027776
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk